argenx reported positive Phase 2 results for FB102 in celiac disease, with the study meeting its primary endpoint and showing a statistically significant improvement versus placebo. 🔹 Key Highlights - 🧬 Primary Endpoint Met: FB102 showed a statistically significant improvement in the villus height-to-crypt depth ratio at Day 78. - 📊 Statistical Result: p=0.0176 versus placebo. - 🔬 Additional Measures: Immune-cell density, tissue scores and symptom measures were consistent with the primary result. - ✅ Safety: No new safety signals were reported. - 🚀 Next Step: argenx plans to advance FB102 into Phase 3. - 📉 Stock Reaction: ARGX shares fell 13.4% overnight. 💡 Why It Matters The positive Phase 2 data supports further development of FB102 in celiac disease, with Phase 3 now planned. However, the sharp share-price decline suggests investors may have been expecting stronger efficacy or a more compelling clinical profile. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified